BRCA2 and prostate cancer: Similarly, BRCA2 CNV detection followed the same pattern: the normal control (CNVs = 1.9 ± 0.1), healthy volunteers (CNVs = 2.0 ± 0.1), and advanced prostate cancer patients with normal CNVs (CNVs = 1.9 ± 0.1) were significantly different from the deletion cells control (CNVs = 1.3 ± 0.1), ambiguous group (CNVs = 1.3 ± 0.04), and the advanced prostate cancer group with deletion CNVs (CNVs = 1.1 ± 0.2).